DK174866B1 - Anvenelse af væksthormonudløsende faktor ved fremstilling af et præparat til diagnose af Alzheimer - Google Patents
Anvenelse af væksthormonudløsende faktor ved fremstilling af et præparat til diagnose af Alzheimer Download PDFInfo
- Publication number
- DK174866B1 DK174866B1 DK198900314A DK31489A DK174866B1 DK 174866 B1 DK174866 B1 DK 174866B1 DK 198900314 A DK198900314 A DK 198900314A DK 31489 A DK31489 A DK 31489A DK 174866 B1 DK174866 B1 DK 174866B1
- Authority
- DK
- Denmark
- Prior art keywords
- growth hormone
- alzheimer
- disease
- composition
- triggering factor
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 title claims description 7
- 238000003745 diagnosis Methods 0.000 title claims description 6
- 230000006870 function Effects 0.000 claims abstract description 6
- 230000003340 mental effect Effects 0.000 claims abstract description 6
- 230000004044 response Effects 0.000 claims description 10
- 206010039966 Senile dementia Diseases 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 4
- 102000018997 Growth Hormone Human genes 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940088597 hormone Drugs 0.000 abstract description 7
- 239000005556 hormone Substances 0.000 abstract description 7
- 230000002267 hypothalamic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 101100424823 Arabidopsis thaliana TDT gene Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 102000005157 Somatostatin Human genes 0.000 description 8
- 108010056088 Somatostatin Proteins 0.000 description 8
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 8
- 229960000553 somatostatin Drugs 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000011835 investigation Methods 0.000 description 3
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000960 hypophysis hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 230000001730 monoaminergic effect Effects 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 230000002263 peptidergic effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000006998 cognitive state Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003100 hypothalamo-hypophyseal system Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005471 regulation of growth hormone secretion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Surgery (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/148,667 US4939124A (en) | 1988-01-26 | 1988-01-26 | Treatment and diagnosis of dementia |
| US14866788 | 1988-01-26 | ||
| US07/206,100 US5089472A (en) | 1988-01-26 | 1988-06-13 | Use of growth hormone releasing factor for improving mental function |
| US20610088 | 1988-06-13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK31489D0 DK31489D0 (da) | 1989-01-25 |
| DK31489A DK31489A (da) | 1989-07-27 |
| DK174866B1 true DK174866B1 (da) | 2004-01-05 |
Family
ID=26846051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198900314A DK174866B1 (da) | 1988-01-26 | 1989-01-25 | Anvenelse af væksthormonudløsende faktor ved fremstilling af et præparat til diagnose af Alzheimer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5089472A (de) |
| EP (1) | EP0326381B1 (de) |
| JP (2) | JP2847098B2 (de) |
| KR (1) | KR970002484B1 (de) |
| CN (1) | CN1055641C (de) |
| AT (1) | ATE106745T1 (de) |
| AU (1) | AU615714B2 (de) |
| CA (1) | CA1341017C (de) |
| DE (1) | DE68915793T2 (de) |
| DK (1) | DK174866B1 (de) |
| FI (1) | FI890389A (de) |
| IL (1) | IL89056A (de) |
| NO (1) | NO890336L (de) |
| RU (1) | RU2024261C1 (de) |
| UA (1) | UA19804A (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022469A1 (en) * | 1993-04-02 | 1994-10-13 | Ohio University | Enhancement of learning and/or memory by a human somatotropin |
| CA2699078A1 (en) * | 2007-09-11 | 2009-04-09 | Dorian Bevec | Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318552D0 (en) * | 1983-07-08 | 1983-08-10 | Sandoz Ltd | Organic compounds |
| US4747825A (en) * | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
| JPH085913B2 (ja) * | 1985-09-12 | 1996-01-24 | ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド | 治療用ソマトスタチン同族体 |
| US4939124A (en) * | 1988-01-26 | 1990-07-03 | Laboratorios Serono S.A. | Treatment and diagnosis of dementia |
-
1988
- 1988-06-13 US US07/206,100 patent/US5089472A/en not_active Expired - Lifetime
-
1989
- 1989-01-23 AU AU28700/89A patent/AU615714B2/en not_active Expired
- 1989-01-24 IL IL8905689A patent/IL89056A/en unknown
- 1989-01-25 KR KR89000761A patent/KR970002484B1/ko not_active IP Right Cessation
- 1989-01-25 JP JP1017386A patent/JP2847098B2/ja not_active Expired - Lifetime
- 1989-01-25 RU SU894613597A patent/RU2024261C1/ru active
- 1989-01-25 UA UA4613597A patent/UA19804A/uk unknown
- 1989-01-25 DK DK198900314A patent/DK174866B1/da not_active IP Right Cessation
- 1989-01-26 EP EP89300751A patent/EP0326381B1/de not_active Expired - Lifetime
- 1989-01-26 FI FI890389A patent/FI890389A/fi not_active Application Discontinuation
- 1989-01-26 CN CN89101534A patent/CN1055641C/zh not_active Expired - Lifetime
- 1989-01-26 AT AT89300751T patent/ATE106745T1/de not_active IP Right Cessation
- 1989-01-26 CA CA000589280A patent/CA1341017C/en not_active Expired - Fee Related
- 1989-01-26 NO NO89890336A patent/NO890336L/no unknown
- 1989-01-26 DE DE68915793T patent/DE68915793T2/de not_active Expired - Lifetime
-
1998
- 1998-02-16 JP JP10032715A patent/JP2965949B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2847098B2 (ja) | 1999-01-13 |
| JPH10251167A (ja) | 1998-09-22 |
| CN1055641C (zh) | 2000-08-23 |
| JP2965949B2 (ja) | 1999-10-18 |
| EP0326381A3 (de) | 1991-08-14 |
| NO890336D0 (no) | 1989-01-26 |
| KR890011572A (ko) | 1989-08-21 |
| IL89056A (en) | 1994-07-31 |
| NO890336L (no) | 1989-07-27 |
| DK31489A (da) | 1989-07-27 |
| DE68915793D1 (de) | 1994-07-14 |
| RU2024261C1 (ru) | 1994-12-15 |
| AU615714B2 (en) | 1991-10-10 |
| UA19804A (uk) | 1997-12-25 |
| KR970002484B1 (en) | 1997-03-05 |
| JPH0242025A (ja) | 1990-02-13 |
| DK31489D0 (da) | 1989-01-25 |
| DE68915793T2 (de) | 1995-03-09 |
| EP0326381B1 (de) | 1994-06-08 |
| ATE106745T1 (de) | 1994-06-15 |
| FI890389A0 (fi) | 1989-01-26 |
| EP0326381A2 (de) | 1989-08-02 |
| CA1341017C (en) | 2000-06-06 |
| AU2870089A (en) | 1989-07-27 |
| CN1036509A (zh) | 1989-10-25 |
| US5089472A (en) | 1992-02-18 |
| IL89056A0 (en) | 1989-08-15 |
| FI890389A (fi) | 1989-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davila et al. | Plasma homovanillic acid as a predictor of response to neuroleptics | |
| Peterson et al. | Ethanol‐induced change in cardiac and endogenous opiate function and risk for alcoholism | |
| Strickland et al. | Comparison of lithium ratio between African-American and Caucasian bipolar patients | |
| DeNucci et al. | Identifying a neurobiologic basis for drug therapy in TMDs | |
| Doran et al. | CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients | |
| Garner et al. | Some visual effects caused by the beverage kava | |
| Lamberts et al. | The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly | |
| Fountoulakis et al. | Neurobiological and psychological correlates of suicidal attempts and thoughts of death in patients with major depression | |
| Banki et al. | Thyroid stimulation test in healthy subjects and psychiatric patients | |
| DK174866B1 (da) | Anvenelse af væksthormonudløsende faktor ved fremstilling af et præparat til diagnose af Alzheimer | |
| Gottardis et al. | The secretion of human growth hormone stimulated by human growth hormone releasing factor following severe cranio-cerebral trauma | |
| Ericksson et al. | Growth hormone responses to the alpha2-adrenoceptor agonist guanfacine and to growth hormone releasing hormone in depressed patients and controls | |
| Schittecatte et al. | Effect of gender and diagnostic on growth hormone response to clonidine for major depression: A large scale multicenter study | |
| Roy | Cortisol nonsuppression in depression: relationship to clinical variables | |
| US4939124A (en) | Treatment and diagnosis of dementia | |
| Poehlau et al. | Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis-outline of a double-blind randomized, placebo-controlled trial | |
| Lu et al. | Correlation between plasma cortisol and CSF catecholamines in endogenous depressed dexamethasone nonsuppressors | |
| Molnar | Seizures associated with high maprotiline serum concentrations | |
| Franceschi et al. | Tuberoinfundibular dopaminergic function in Parkinson’s disease | |
| del Campo et al. | Diurnal variations in endocrine and psychological responses to 0.2 mg/kg naloxone administration in patients with major depressive disorder and matched controls | |
| Atkinson Jr et al. | Neuroendocrine function and endogenous opioid peptide systems in chronic pain | |
| Chaney et al. | Cognitive deficit in middle-aged alcoholics | |
| Frank et al. | Mania in a girl with Cushing's disease | |
| Luijckx et al. | Parkinsonism in alcohol withdrawal: case report and review of the literature | |
| De Wied et al. | Several aspects of the influence of vasopressin on pituitary-adrenal activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |